Patents by Inventor Shiow-Lin Pan
Shiow-Lin Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9029394Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: GrantFiled: May 13, 2013Date of Patent: May 12, 2015Assignee: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Patent number: 9023867Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: GrantFiled: May 13, 2013Date of Patent: May 5, 2015Assignee: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Patent number: 9023866Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: GrantFiled: May 13, 2013Date of Patent: May 5, 2015Assignee: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Patent number: 8710062Abstract: This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.Type: GrantFiled: February 24, 2012Date of Patent: April 29, 2014Assignee: Taipei Medical UniversityInventors: Hui-po Wang, Che-Ming Teng, Chun-Li Wang, Jih-hwa Guh, Shiow-Lin Pan, Yuan-Yi Wang, Jang-Feng Lian
-
Publication number: 20130252999Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: ApplicationFiled: May 13, 2013Publication date: September 26, 2013Applicant: China Medical UniversityInventors: Sheng-Chu KUO, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Publication number: 20130253006Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: ApplicationFiled: May 13, 2013Publication date: September 26, 2013Applicant: China Medical UniversityInventors: Sheng-Chu KUO, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Publication number: 20130244983Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: ApplicationFiled: May 13, 2013Publication date: September 19, 2013Applicant: China Medical UniversityInventors: Sheng-Chu KUO, Che-Ming TENG, Kuo-Hsiung LEE, Li-Jiau HUANG, Li-Chen CHOU, Chih-Shiang CHANG, Chung-Ming SUN, Tian-Shung WU, Shiow-Lin PAN, Tzong-Der WAY, Jang-Chang LEE, Jing-Gung CHUNG, Jai-Sing YANG, Chien-Ting CHEN, Ching-Che HUANG, Shih-Ming HUANG
-
Patent number: 8501957Abstract: Benzimidazole compounds of formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z1, and Z2 are defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.Type: GrantFiled: December 10, 2009Date of Patent: August 6, 2013Assignee: China Medical UniversityInventors: Chih-Shiang Chang, Jih-Hwa Guh, Che-Ming Teng, Shiow-Lin Pan, Wei-Ling Chang, Ju-Fang Liu, Kai-Wei Chang, Sheng-Chu Kuo
-
Patent number: 8440692Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and ?/, ?/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: GrantFiled: December 7, 2007Date of Patent: May 14, 2013Assignee: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Publication number: 20120232088Abstract: This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.Type: ApplicationFiled: February 24, 2012Publication date: September 13, 2012Applicants: National Taiwan University, Taipei Medical UniversityInventors: Hui-Po Wang, Che-Ming Teng, Chun-Li Wang, Jih-hwa Guh, Shiow-Lin Pan, Yuan-Yi Wang, Jang-Feng Lian
-
Publication number: 20100179147Abstract: Benzimidazole compounds of formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z1, and Z2 are defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.Type: ApplicationFiled: December 10, 2009Publication date: July 15, 2010Inventors: Chih-Shiang Chang, Jih-Hwa Guh, Che-Ming Teng, Shiow-Lin Pan, Wei-Ling Chang, Ju-Fang Liu, Kai-Wei Chang, Sheng-Chu Kuo
-
Patent number: 7754751Abstract: A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R1, R2, R3, R4, R5, and R6, independently, is R?, nitro, halogen, —C(O)—OR?, —C(O)—SR?, —C(O)—NR?R?, —(CH2)mOR?, —(CH2)mSR?, —(CH2)mNR?R?, —(CH2)mCN, —(CH2)mC(O)—OR?, —(CH2)mC(O)H, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are —O(CH2)nO—, in which each of R? and R?, independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-?B with such a compound.Type: GrantFiled: March 15, 2005Date of Patent: July 13, 2010Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Che-Ming Teng, Jih-Hwa Guh, Shiow-Lin Pan, Sheng-Chu Kuo, Fang-Yu Lee
-
Publication number: 20100168064Abstract: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and ?/, ?/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.Type: ApplicationFiled: December 7, 2007Publication date: July 1, 2010Applicant: China Medical UniversityInventors: Sheng-Chu Kuo, Che-Ming Teng, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Chih-Shiang Chang, Chung-Ming Sun, Tian-Shung Wu, Shiow-Lin Pan, Tzong-Der Way, Jang-Chang Lee, Jing-Gung Chung, Jai-Sing Yang, Chien-Ting Chen, Ching-Che Huang, Shih-Ming Huang
-
Patent number: 7378532Abstract: A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.Type: GrantFiled: November 29, 2004Date of Patent: May 27, 2008Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Fang-Yu Lee, Che-Ming Teng, Li-Jiau Huang, Li-Chen Chou, Jih-Hwa Guh, Shiow-Lin Pan
-
Publication number: 20070149554Abstract: A method for treating cancer, which includes administrating to a subject in need thereof an effective amount of a chemotherapeutic agent and an effective amount of a compound of the formula: in which, A is H or each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, (CH2)mC(O)N(OR)R?, N(OR)R?, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: December 21, 2006Publication date: June 28, 2007Applicant: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Che-Ming Teng, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Publication number: 20070142449Abstract: A method for treating an angiogenesis-related disorder or cancer. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC)O)OR, (CH2)mCHO, (CH2)mCH?NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: January 3, 2007Publication date: June 21, 2007Applicant: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Che-Ming Teng, Sheng-Chu Kuo, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Patent number: 7166293Abstract: A method for treating an angiogenesis-related disorder. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: GrantFiled: May 16, 2002Date of Patent: January 23, 2007Assignee: Carlsbad Technology, Inc.Inventors: Che-Ming Teng, Sheng-Chu Kuo, Fang Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Publication number: 20050215613Abstract: A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R1, R2, R3, R4, R5, and R6, independently, is R?, nitro, halogen, —C(O)—OR?, —C(O)—SR?, —C(O)—NR?R?, —(CH2)mOR?, —(CH2)mSR?, —(CH2)mNR?R?, —(CH2)mCN, —(CH2)mC(O)—OR?, —(CH2)mC(O)H, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are —O(CH2)nO—, in which each of R? and R?, independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-?B with such a compound.Type: ApplicationFiled: March 15, 2005Publication date: September 29, 2005Inventors: Che-Ming Teng, Jih-Hwa Guh, Shiow-Lin Pan, Sheng-Chu Kuo, Fang-Yu Lee
-
Publication number: 20050215612Abstract: A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.Type: ApplicationFiled: November 29, 2004Publication date: September 29, 2005Inventors: Sheng-Chu Kuo, Fang-Yu Lee, Che-Ming Teng, Li-Jiau Huang, Li-Chen Chou, Jih-Hwa Guh, Shiow-Lin Pan
-
Publication number: 20050209252Abstract: This invention relates to a method for treating cancer including administrating to a subject in need thereof an effective amount of a compound of the formula: wherein, A is H or each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, (CH2)mC(O)N(OR)R?, N(OR)R?, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: May 18, 2005Publication date: September 22, 2005Inventors: Che-Ming Teng, Sheng-Chu Kuo, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh